Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid

Anticancer Research

Volumn 22, Issue 6 B, 2002, Pages 3449-3455

  Jansman, Frank G A ^a   Coenen, Jules L L M ^a   De Graaf, Jacques C ^a   Tobi, Hilde ^a,b   Sleijfer, Dirk T ^b,c   Brouwers, Jacobus R B J ^a,b  

^a Isala Klinieken ^*  (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Area Under Curve; Chemotherapy; Colorectal cancer; Drug toxicity; Fluorouracil; Folinic acid; Oral mucositis; Pharmacokinetics; Plasma; Saliva

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; CLINICAL ARTICLE; COLORECTAL CANCER; CONJUNCTIVITIS; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; FEMALE; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MUCOSA INFLAMMATION; NAUSEA; PREDICTION; PRIORITY JOURNAL; SALIVA ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; SALVIA;

EID: 0036875897     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Midgley R and Kerr D: Colorectal cancer. Lancet 353: 391-399, 1999.
2. Evans RM, Laskin JD and Hakala MT: Effect of excess folates and deoxynosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288-3295, 1981.
3. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
4. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 321: 531-535, 2000.
5. Jansman FGA, Sleijfer DT, Coenen JLLM, De Graaf JC and Brouwers JRBJ: Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf 23: 255-278, 2000.
6. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK et al.: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407-1417, 1989.
7. Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH and Rosenfeld JM: Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 38: 719-724, 1978.
8. Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramaioli A and Demard F: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12: 1291-1295, 1994.
9. Schneider M, Etinne MC, Milano G, Thyss A, Otto J, Dassonville O et al.: Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 13: 1656-1662, 1995.
10. Vokes EE, Mick R, Kies MS, Dolan ME, Malone D, Athanasiadis I et al.: Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 14: 1663-1671, 1996.
11. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC et al.: Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77: 441-451, 1996.
12. Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P et al.: 5-FU therapeutic monitoring with dose adjustments leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59: 287-290, 1989.
13. Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G et al.: Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 12: 1301-1306, 2001.
14. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C et al.: Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 16: 1470-1478, 1998.
15. Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T et al.: Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 4: 2039-2045, 1998.
16. Celio LA, DiGregorio GJ, Ruch E, Pace J and Piraino AJ: Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. Eur J Clin Pharmacol 24: 261-266, 1983.
17. Joulia JM, Pinguet F, Ychou M, Duffour J, Astre C and Bressolle F: Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. Eur J Cancer 35: 296-301, 1999.
18. Milano G, Thyss A, Santini J, Frenay M, Francois E, Schneider M et al.: Salivary passage of 5-fluorouracil during continuous infusion. Cancer Chemother Pharmacol 24: 197-199, 1989.
19. Joulia JM, Pinguet F, Grosse PY, Astre C and Bressolle F: Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study. J Chromatogr B 692: 427-435, 1997.
20. Proost JH and Meijer DK: MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22: 1155-1163, 1992.
21. International Common Toxicity Criteria, version 2.0. National Cancer Institute, http://ctep.info.nih.gov/CTC3default.htm
22. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J and Christian MC: Accelerated titration design for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147, 1997.
23. Milano G, Roman P, Khater R, Frenay M, Renee N and Namer M: Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 41: 537-541, 1988.
24. Thyss A, Milano G, Renee N, Vallicioni J, Schneider M and Demard F: Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16: 64-66, 1986.
25. Pinedo HM and Peters GJ: Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653-1664, 1988.
26. Etienne MC, Chatelut E, Pivot X, Lavit M, Pujol A, Canal P et al.: Co-variables influencing 5-fluorouracil clearance during continuous infusion. A NONMEM analysis. Eur J Cancer 34: 92-97, 1998.
27. McLeod HL, Sludden J, Hardy SC, Lock RE, Hawksworth GM and Cassidy J: Autoregulation of 5-fluorouracil metabolism. Eur J Cancer 10: 1623-1627, 1998.
28. Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, Fety-Deporte R et al.: Dose and time-dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther 68: 270-279, 2000.
29. Grem JL, Quinn M, Ismail AS, Takimoto CH, Lush R, Liewehr DJ et al.: Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion. Cancer Chemother Pharmacol 47: 117-125, 2001.
30. Jansman FGA, Sleijfer DT, De Graaf JC, Coenen JLLM and Brouwers JRB: Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf 24: 353-367, 2001.